

Nivo/Ipi (nivolumab and ipilimumab) CheckMate 214

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Nivo/Ipi (nivolumab and ipilimumab) CheckMate 214

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers

Therapeutic Indication: First-line treatment of adult patients with intermediate/poor-risk advanced RCC

Experimental Arm: Nivo/Ipi (nivolumab and ipilimumab)

Control Arm: Sunitinib

